Rosiglitazone (trade name Avandia) is an antidiabetic drug in the thiazolidinedione class. It works as an insulin sensitizer, by binding to the PPAR in fat cells and making the cells more responsive to insulin. More
Rosiglitazone (trade name Avandia) is an antidiabetic drug in the thiazolidinedione class. It works as an insulin sensitizer, by binding to the PPAR in fat cells and making the cells more responsive to insulin.
Rosiglitazone
Rosiglitazone; 122320-73-4; Avandia; 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione; Brl-49653
Enselin, Glitos, Reglit, Rezult, Risicon- G, Roglin, Rosicon, Rosinorm, Rositec, Rosizon, Ross, Rozon, Secrin- R, Senzia
5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione
PPAR-gamma receptors activation regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. It is a potent and highly selective agonist at PPAR (peroxisome proliferator activated receptors) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.
4 mg daily may increase after 8-12 weeks of therapy according to response.
Type 2 diabetes mellitus.
Upper respiratory tract infections, headache, back pain, hyperglycaemia, fatigue, sinusitis, diarrhoea, hypoglycaemia, oedema, anaemia, weight gain.
Store at 25°C
357.427
C18H19N3O3S
122320-73-4